Increasing Dose Safety Study of Hemospan in Orthopedic Surgery Patients

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the safety and possible effectiveness of Hemospan solution in patients undergoing elective orthopedic surgery who receive spinal anesthesia.

Clinical Trial Description

Allogeneic (donor) blood transfusions are often required during and/or after orthopedic hip surgery to maintain adequate hemoglobin concentration, prevent tissue ischemia, treat hypotension, and compensate for fluid shifts. For example, during hospitalization for hip replacement, patients may receive up to two to three units of blood. This amount varies depending on the technical difficulty of the surgery, the patient's hemoglobin concentration prior to surgery, and the patient's clinical status.

The limited availability, logistic constraints and documented risks associated with allogeneic blood transfusions have prompted the search for alternative therapies. Autologous (self-donated) red blood cell pre-donation can be used in many cases but age, anemia and co-morbidities often preclude the use of this treatment. Cell saving and re-infusion also prevents blood transfusion, but this practice also has potential problems and limited applicability.

Over the past 75 years various "blood substitutes" have been developed for potential clinical use. To date all have shown significant toxicity in preclinical or clinical studies and regulatory approval of these synthetic or hemoglobin-based products has been impeded by safety concerns.

Hemospan is a novel polyethylene-modified hemoglobin solution specifically developed to perfuse and oxygenate tissue at risk for ischemia and hypoxia. As a result of the molecular size and oxygen dissociation characteristics, Hemospan selectively off-loads oxygen in tissues predisposed to low oxygen tension. In preclinical studies Hemospan has been found to be free of significant toxicity in a variety of animal species in doses exceeding those that will be used in this study.

In the Phase I safety study in normal volunteers, Hemospan was well tolerated in doses up to 100 mg/kg (approximately 200 mL of a 4g/dL Hemospan solution). ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00494949
Study type	Interventional
Source	Sangart
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	April 2003
Completion date	August 2006

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04062994` - A Clinical Decision Support Trial to Reduce Intraoperative Hypotension
Active, not recruiting	`NCT02016599` - Effects of Transitional Circulation in ELBW Infants
Recruiting	`NCT05836610` - Hydrocortisone Therapy Optimization During Hypothermia Treatment in Asphyxiated Neonates	Phase 4
Completed	`NCT02907931` - Carotid Doppler Ultrasound for the Measurement of Intravascular Volume Status	N/A
Suspended	`NCT02315937` - Hemodynamic Assessment During Spinal Anesthesia Using Transthoracic Echocardiography'	N/A
Completed	`NCT03215797` - Phenylephrine or Norepinephrine for a Better Hemodynamic Stability	Phase 3
Recruiting	`NCT02532270` - Detecting Hypotension By Continuous Non-invasive Arterial Pressure Monitoring	N/A
Completed	`NCT02802683` - Hemodynamic Impact of Hyperbaric Versus Isobaric for Spinal Anesthesia During Cesarean Delivery	Phase 4
Completed	`NCT02437799` - Dicrotic Notch and Hypotension at Caesarean Under Spinal Anaesthesia	N/A
Not yet recruiting	`NCT01941472` - Transcutaneous pO2, Transcutaneous pCO2 and Central Venous pO2 Variations to Predict Fluid Responsiveness	N/A
Completed	`NCT02146898` - The Severity Of Hypotension Comparing Three Positions During Spinal Anesthesia For Cesarean Delivery	N/A
Completed	`NCT01930227` - Transcutaneous Electrical Acupoint Stimulation(TEAS) for Hypotension After Spinal Anesthesia in Parturients	N/A
Recruiting	`NCT01434251` - Treatment of Hypotension of Prematurity (TOHOP)	N/A
Completed	`NCT01592669` - Passive Leg Raising Attenuates and Delays Tourniquet Deflation-induced Hypotension and Tachycardia	N/A
Withdrawn	`NCT01183741` - Accuracy of Non-Invasive Blood Pressure Measurement in Adults	Phase 3
Completed	`NCT00991627` - Different Approaches to Maternal Hypotension During Cesarean Section	Phase 4
Withdrawn	`NCT00750516` - Lactic Acid Levels In Hypotensive Patients Without(Standard) and With Tourniquet
Completed	`NCT00115726` - Trial Assessing the Effect of Preoperative Furosemide on Intraoperative Blood Pressure	Phase 4
Recruiting	`NCT05513066` - Management Arterial Hypotension During Planned Caesarean Section, Intravenous Ephedrine/Phenylephrine Mixture Versus Intravenous Baby Noradrenaline
Completed	`NCT04089644` - Manual vs Closed-loop Control of Mean Arterial Pressure	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.